Eli Lilly and Company
Q3 2022 Earnings Call
Nov 01, 2022, 9:00 a.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q3 2022 earnings conference call. [Operator instructions] And as a reminder, your conference is being recorded. I would now like to turn the conference over to your host, Joe Fletcher, senior vice president of investor relations. Please go ahead.
Joe Fletcher -- Senior Vice President, Investor Relations
Thank you, Lois, and good morning. Thank you for joining us for Eli Lilly and Company's Q3 2022 earnings call. I'm Joe Fletcher, senior vice president of investor relations. And joining me on today's call are Dave Ricks, Lilly's chair and CEO; Anat Ashkenazi, chief financial officer; Dr.
Additional information concerning factors that could cause actual results to differ materially is contained in our latest Form 10-K and subsequent Forms 10-Q and 8-K filed with the Securities and Exchange Commission. The information we provide about our products and pipeline is for the benefit of the investment community. It is not intended to be promotional and is not sufficient for prescribing decisions. As we transition to our prepared remarks, please note that our commentary will focus on non-GAAP financial measures.
Now I'll turn the call over to Dave.
Dave Ricks -- Chairman and Chief Executive Officer
Well, thanks, Joe. Over the last three months, we continued to successfully execute our strategy. On the commercial front, we drove strong volume-based growth of our recently launched medicines, including Mounjaro, which has seen an impressive initial uptick. At the same time, we advanced our late-phase pipeline progressing toward potential launches of four new medicines by the end of next year while also investing in our early stage pipeline and new modalities like gene therapy.
To meet the growing demand for our products and prepare for future launches, we have also continued to invest in expansion of our manufacturing footprint. I'd highlight two areas of high unmet need where Lilly is progressing new medicines to improve patient outcomes, obesity and Alzheimer's disease. In obesity, we are pleased that the FDA has granted Fast Track designation for tirzepatide for adults with obesity, enabling us to potentially bring this promising medicine to patients even sooner. We're also initiating Surmount MMO, our Phase 3 morbidity and mortality and obesity study to evaluate improved outcomes for patients with obesity.